CA2284170A1 - Identification d'agents utiles dans le traitement de la maladie d'alzheimer - Google Patents
Identification d'agents utiles dans le traitement de la maladie d'alzheimer Download PDFInfo
- Publication number
- CA2284170A1 CA2284170A1 CA002284170A CA2284170A CA2284170A1 CA 2284170 A1 CA2284170 A1 CA 2284170A1 CA 002284170 A CA002284170 A CA 002284170A CA 2284170 A CA2284170 A CA 2284170A CA 2284170 A1 CA2284170 A1 CA 2284170A1
- Authority
- CA
- Canada
- Prior art keywords
- alzheimer
- disease
- treatment
- identification
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000002831 pharmacologic agent Substances 0.000 abstract 1
- 230000006950 reactive oxygen species formation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81612297A | 1997-03-11 | 1997-03-11 | |
US08/816,122 | 1997-03-11 | ||
PCT/US1998/004683 WO1998040071A1 (fr) | 1997-03-11 | 1998-03-11 | Identification d'agents utiles dans le traitement de la maladie d'alzheimer |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2284170A1 true CA2284170A1 (fr) | 1998-09-17 |
CA2284170C CA2284170C (fr) | 2008-12-02 |
Family
ID=25219748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002284170A Expired - Fee Related CA2284170C (fr) | 1997-03-11 | 1998-03-11 | Identification d'agents utiles dans le traitement de la maladie d'alzheimer |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1007048A4 (fr) |
JP (1) | JP2001514661A (fr) |
AU (1) | AU748768B2 (fr) |
CA (1) | CA2284170C (fr) |
WO (1) | WO1998040071A1 (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6743771B2 (en) * | 1995-12-29 | 2004-06-01 | Novactyl, Inc. | Methods and compositions for controlling protein assembly or aggregation |
US7045531B1 (en) | 1997-03-11 | 2006-05-16 | The General Hospital Corporation | Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator |
EA002526B1 (ru) | 1997-08-21 | 2002-06-27 | П.Н.Геролиматос С.А. | Применение фанхинона для лечения болезни альцгеймера |
WO1999018432A1 (fr) | 1997-10-06 | 1999-04-15 | The General Hospital Corporation | Techniques de criblage de medicaments permettant de predire la dyskinesie tardive |
US6323218B1 (en) * | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
US6638711B1 (en) * | 1999-04-29 | 2003-10-28 | The General Hospital Corporation | Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation |
WO2000018392A1 (fr) | 1998-09-25 | 2000-04-06 | Glycox Corporation Limited | Fructosamine-oxydase: antagonistes et inhibiteurs |
DK1140090T3 (da) | 1999-01-07 | 2005-04-18 | Gerolymatos P N Sa | Anvendelse af phanquinon til behandlingen eller hindringen af hukommelsessvigt |
DE19909357A1 (de) * | 1999-03-03 | 2000-09-07 | Gerd Multhaup | Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt |
EP1200470B1 (fr) * | 1999-08-04 | 2004-11-24 | The University Of Southern California | Assemblage de proteine amyloide b globulaire et ses utilisations |
US20030138374A1 (en) * | 2000-03-22 | 2003-07-24 | Yukitsuda Kudo | Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same |
AUPR976401A0 (en) * | 2001-12-27 | 2002-01-31 | Alzhyme Pty Ltd | Agents for the treatment of alzheimer's disease and screening methods for the same |
AU2002351880B2 (en) * | 2001-12-27 | 2007-08-30 | Neuroscientific Biopharmaceuticals Pty Ltd | Screening methods and the use of agents identified using the same |
JP4860906B2 (ja) | 2002-03-08 | 2012-01-25 | プロテミックス コーポレイション リミティド | 心疾患および/または関連心不全の予防および/または治療 |
WO2004017956A1 (fr) | 2002-08-20 | 2004-03-04 | Protemix Corporation Limited | Formes posologiques et traitements s'y rapportant |
JP2006520768A (ja) * | 2003-03-21 | 2006-09-14 | パリュメ エス アー | 金属イオンのキレート化剤として有用な窒素含有多環式誘導体およびそれらの用途 |
CA2536393A1 (fr) * | 2003-09-09 | 2005-06-16 | Gilead Sciences, Inc. | Utilisation de liposomes, qui sont de petites vesicules monofeuillets, pour l'elimination d'une entite d'un echantillon biologique |
US20050159364A1 (en) * | 2003-12-19 | 2005-07-21 | Cooper Garth J. | Copper antagonist compounds |
US7582796B2 (en) | 2004-07-19 | 2009-09-01 | Protemix Corporation Limited | Synthesis of triethylenetetramines |
GEP20105110B (en) | 2004-08-03 | 2010-11-10 | Transtech Pharma Inc | Rage fusion proteins and their use |
EP2380983A3 (fr) | 2006-05-05 | 2012-12-05 | TransTech Pharma Inc. | Protéines de fusion RAGE, formulations et procédés d'utilisation correspondants |
US8338089B2 (en) | 2006-11-20 | 2012-12-25 | The Johns Hopkins University | Method of inhibiting lentiviral infectivity utilizing zinc chelation to inhibit Vif activity |
RU2513695C2 (ru) | 2007-06-14 | 2014-04-20 | Гэлэктика Фармасьютикалс, Инк. | Слитые белки rage |
WO2009108999A1 (fr) | 2008-03-03 | 2009-09-11 | Ross Stewart Grant | Formulations pharmaceutiques de resvératrol et procédés d'utilisation de celles-ci pour traiter des troubles cellulaires |
CA2757079C (fr) | 2009-04-20 | 2015-05-19 | Pfizer Inc. | Controle de la glycosylation de proteines, compositions et methodes associees |
WO2018236221A2 (fr) * | 2017-06-03 | 2018-12-27 | Can Holding B.V. | Dissolution de dépôt de peptide neurodégénératif |
KR102048846B1 (ko) * | 2017-11-20 | 2019-11-27 | 한국생명공학연구원 | 혈관 질환 치료제 및 이의 스크리닝 방법 |
JPWO2021015300A1 (fr) * | 2019-07-25 | 2021-01-28 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5434050A (en) * | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
AU669493B2 (en) * | 1991-11-12 | 1996-06-13 | University Of Melbourne, The | A method for assaying and treating Alzheimer's disease |
US5688516A (en) * | 1992-11-12 | 1997-11-18 | Board Of Regents, The University Of Texas System | Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices |
JPH07149668A (ja) * | 1993-11-30 | 1995-06-13 | Kanegafuchi Chem Ind Co Ltd | アミロイド沈着検出用物質 |
US5688651A (en) * | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
ATE218583T1 (de) * | 1995-03-14 | 2002-06-15 | Praecis Pharm Inc | Verbindungen mit aggregations-modulierenden wirkung auf das amyloid protein |
US6043224A (en) * | 1996-09-05 | 2000-03-28 | The Massachusetts Institute Of Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
-
1998
- 1998-03-11 JP JP53971898A patent/JP2001514661A/ja not_active Ceased
- 1998-03-11 WO PCT/US1998/004683 patent/WO1998040071A1/fr active IP Right Grant
- 1998-03-11 CA CA002284170A patent/CA2284170C/fr not_active Expired - Fee Related
- 1998-03-11 EP EP98911551A patent/EP1007048A4/fr not_active Withdrawn
- 1998-03-11 AU AU65484/98A patent/AU748768B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
WO1998040071A1 (fr) | 1998-09-17 |
AU748768B2 (en) | 2002-06-13 |
EP1007048A4 (fr) | 2004-09-22 |
JP2001514661A (ja) | 2001-09-11 |
CA2284170C (fr) | 2008-12-02 |
EP1007048A1 (fr) | 2000-06-14 |
AU6548498A (en) | 1998-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2284170A1 (fr) | Identification d'agents utiles dans le traitement de la maladie d'alzheimer | |
CA2323458A1 (fr) | Agents utilises pour traiter la maladie d'alzheimer | |
CA2289531A1 (fr) | Composition et procedes de traitement de la maladie d'alzheimer et autres amyloidoses | |
AU2002219824A1 (en) | Compositions and methods for diagnosing alzheimer's disease | |
HUP0103654A2 (hu) | Szmilagenin és/vagy anzurogenin-D alkalmazása Alzheimer-kór kezelésére szolgáló gyógyszerkészítmény előállítására | |
WO1998022494A3 (fr) | METHODES ET COMPOSES DESTINES A INHIBER LA LIBERATION ET/OU LA SYNTHESE DU PEPTIDE β-AMYLOIDE | |
BG103740A (en) | Phytostyrene composition for the prevention of the alzheimer's disease | |
AU1407399A (en) | Treatment for alzheimer's disease | |
ZA968476B (en) | Cleansing compositions with dendrimers as mildness agents. | |
AU3113500A (en) | Compositions for treating alzheimer's disease and other amyloidoses | |
CA2311356A1 (fr) | Procede pour le traitement de la maladie d'alzheimer | |
ZA977310B (en) | Transdermal propentofylline compositions for the treatment of Alzheimer's disease. | |
AU2002335794A1 (en) | Allylamides useful in the treatment of alzheimer's disease | |
CA2290101A1 (fr) | Utilisation de la tourmaline dans des compositions cosmetiques de nettoyage | |
AU2002315131A1 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
NO20001869D0 (no) | Fremgangsmõte for behandling av Alzheimerssykdom | |
DE59504401D1 (de) | Johanniskrautextrakte | |
CA2301706A1 (fr) | Utilisation de phanquinone dans le traitement de la maladie d'alzheimer | |
AU3068899A (en) | Diagnostic assay for late-onset alzheimer's disease | |
AU1405899A (en) | Treatment for alzheimer's disease | |
PL345697A1 (en) | Method for the production of n,n'-carbonyl diazoles | |
AU2001248760A1 (en) | Preventives/remedies for alzheimer's disease | |
DE69805988D1 (de) | Herstellung von 1,3-diaminopentan durch hydrierung von 3-aminopentanitril | |
ZA971716B (en) | 1,1,2-triphenylbut-1-ene derivatives for treating alzheimer's disease | |
EP1181550A4 (fr) | Procedes d'identification de composes pour le traitement de la maladie d'alzheimer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |